Here we document the role of MDC1 (mediator of DNA damage checkpoint 1) in the detection and repair of human and mouse telomeres rendered dysfunctional through inhibition of TRF2. Consistent with its role in promoting DNA damage foci, MDC1 knockdown affected the formation of telomere dysfunction-induced foci (TIFs), diminishing the accumulation of phosphorylated ATM, 53BP1, Nbs1, and to a lesser extent, ␥-H2AX. In addition to this effect on TIFs, the rate of nonhomologous end-joining (NHEJ) of dysfunctional telomeres was significantly decreased when MDC1 itself or its recruitment to chromatin was inhibited. MDC1 appeared to promote a step in the NHEJ pathway after the removal of the 3 telomeric overhang. The acceleration of NHEJ was unlikely to be due to increased presence of 53BP1 and Mre11 in TIFs, since knockdown of neither factor affected telomere fusions. Furthermore, relevant cell cycle effectors (Chk2, p53, and p21) of the ATM kinase pathway were unaffected and there was no change in the rate of cell cycle progression. We propose that the binding of MDC1 to ␥-H2AX directly affects NHEJ in a manner that is independent of the ATM-dependent cell cycle arrest pathway. 
Results and Discussion
MDC1 (mediator of DNA damage checkpoint 1) is a recently identified mammalian DNA damage response factor with an important role in the DNA damage response (Goldberg et al. 2003; Stewart et al. 2003; Lukas et al. 2004 ; for review, see Stucki and Jackson 2006) . MDC1 is recruited to chromatin near sites of DNA damage through the interaction of its BRCA1 C-terminal (BRCT) repeats with ␥-H2AX, the phosphorylated form of H2AX Lee et al. 2005; Stucki et al. 2005) . Chromatin-bound MDC1 facilitates the recruitment of the ATM kinase to sites of DNA damage, leading to additional H2AX phosphorylation, which in turn recruits more MDC1 (Stucki et al. 2005; Bekker-Jensen et al. 2006; Lou et al. 2006) . MDC1 also interacts with the Mre11/Rad50/Nbs1 complex and promotes its stable association with sites of DNA damage (Goldberg et al. 2003) , which could explain how MDC1 enhances the local action of the ATM kinase. Thus, MDC1 appears to be part of a feed-forward loop that promotes the stable association of DNA damage response factors in large domains (foci) near the site of damage (Stucki et al. 2005; Lou et al. 2006) . However, the function of such DNA damage response foci, the role of the foci in the regulation of cell cycle progression, and their contribution to DNA repair have remained ill-defined (Stucki and Jackson 2006) . Here we examine the contribution of MDC1 to the detection and processing of a specific form of DNA damage, chromosome ends lacking telomere protection. The results point to a direct role for MDC1 in the repair of dysfunctional telomeres through nonhomologous endjoining (NHEJ).
The protective function of telomeres can be disrupted through inhibition of the shelterin protein TRF2 with a dominant-negative allele or through deletion of the mouse TRF2 gene (for review, see de Lange 2005) . Cells respond to the resulting unprotected chromosome ends as if they were double-strand breaks (DSBs). DNA damage factors such as 53BP1, ␥-H2AX, ATM phosphorylated at S1981 (ATM-S1981-P), and the Mre11/Nbs1/Rad50 complex accumulate in telomere dysfunction-induced foci (TIFs) that extend from the dysfunctional telomere into the subtelomeric regions (d'Adda di Fagagna et al. 2003; Takai et al. 2003; Celli and de Lange 2005) . Telomere damage also activates the ATM kinase signaling cascade, resulting in p53-mediated arrest before DNA replication, and the deprotected chromosome ends are processed by DNA repair pathways, resulting in telomere fusions. The pathway leading to telomere fusions was identified as NHEJ based on the 100-fold diminished fusion rate in the absence of DNA ligase IV (Celli and de Lange 2005) and the 10-fold reduction in cells lacking Ku70 (Celli et al. 2006) . Thus, both the DNA damage signaling pathway and the DNA damage repair reactions elicited by TRF2 loss resemble the canonical response to DSBs. In diploid mammalian cells, TRF2 inhibition typically generates 10-90 ␥-H2AX foci (Takai et al. 2003; Celli and de Lange 2005) , which is a moderate insult equivalent to the number of DSBs resulting from irradiation with 0.25-2.5 Gy (Rothkamm and Lobrich 2003) .
MDC1 was readily observed at telomeres when their function was compromised. Telomere deprotection was induced by Cre-mediated deletion of a conditional TRF2 allele (TRF2F/−) (Celli and de Lange 2005) from mouse embryo fibroblasts (MEFs). For these initial experiments, we used cells lacking DNA ligase IV (lig4) in order to block telomere fusions Celli and de Lange 2005) , and the MEFs also lacked a functional p53 pathway, abrogating their G1/S arrest . Upon deletion of TRF2 from such TRF2F/− lig4 −/− p53 −/− cells, MDC1 formed large TIFs that coincided with 53BP1 TIFs (Fig.  1A) . Similarly, MDC1 localized to TIFs in human cells after adenoviral introduction of TRF2-DN (Supplementary Fig. 1A ), a dominant-negative allele of TRF2 (van Steensel et al. 1998; Karlseder et al. 1999) . In contrast, MDC1 was not localized at chromosome ends in cells with telomere protection (Fig. 1A; Supplementary Fig.  1A ). Furthermore, telomeric DNA was not recovered in chromatin immunoprecipitation (ChIP) on cells expressing Flag-tagged MDC1 ( Supplementary Fig. 1B ). MDC1 binds to the Mre11/Rad50/Nbs1 complex (Goldberg et al. 2003) , which associates with TRF2 and is present at functional human telomeres (Zhu et al. 2000) . However, we found no indication that MDC1 contributed to the association of the Mre11 complex with TRF2. No association between MDC1 and TRF2 or other shelterin components was detected in immunoprecipitations (IPs) of endogenous proteins or overexpressed proteins ( Supplementary Fig. 1C,D ; data not shown), and MDC1 knockdown did not affect the association of Mre11 with TRF2 ( Supplementary Fig. 1E ). These data argue that MDC1 is not a constitutive component of functional telomeres but accumulates at telomeres that have been rendered dysfunctional through inhibition of TRF2.
To examine the role of MDC1 in the telomere damage response, we targeted MDC1 with short hairpin RNAs (shRNAs). Immunofluorescence (IF) indicated a significant reduction in mouse MDC1 levels after treatment with two independent shRNAs, sh4 and sh5 (Supplementary Fig. 2A ), and RT-PCR indicated a 75%-90% decrease in the MDC1 mRNA levels ( Supplementary Fig. 2B ). As expected, knockdown of mouse MDC1 abrogated the recruitment of 53BP1 and ATM-S1981-P to dysfunctional mouse telomeres (Fig. 1B,C) . In the shRNA-treated cells, 53BP1 and ATM-S1981-P remained diffuse and homogenous, while in control cells, both localized to telomeres and formed bright foci. Quantification of the TIF response indicated that MDC1 knockdown led to a sevenfold to 10-fold reduction in the frequency of cells with more than five 53BP1 or ATM-S1981-P foci at dysfunctional telomeres (Fig. 1E) . TIF formation by ␥-H2AX was affected to a lesser extent by MDC1 knockdown (Fig. 1D,E) showing a reduction from ∼60% to ∼40% in the fraction of cells that were ␥-H2AX TIF positive and there was a reduction in the size and/or intensity of the ␥-H2AX foci. The same results were obtained with down-regulation of human MDC1 with two independent shRNAs in primary and transformed human cells (Supplementary Fig. 3A ). MDC1 knockdown resulted in diminished TIF formation by 53BP1, ATM-S1981-P, and Nbs1-S343-P, accompanied by a more modest effect on ␥-H2AX (Supplementary Fig. 3B ; data not shown). These results were further confirmed though inhibition of MDC1 with a dominant-negative allele, MDC1-FHA (Goldberg et al. 2003; Xu and Stern 2003) . Overexpression of MDC1-FHA inhibited 53BP1 TIF formation in normal human fibroblasts as well as in A-T (ATM-deficient) cells and in Seckel syndrome cells, which are hypomorphic for ATR (Supplementary Fig. 4 ; O'Driscoll et al. 2003) . Collectively, these data indicate that MDC1 promotes the formation of foci containing ATM-S1981-P, 53BP1, Nbs1, and ␥-H2AX at dysfunctional telomeres, as it does at DSBs.
Dysfunctional telomeres undergo end-toend fusions that are mediated by the NHEJ factors DNA ligase IV and Ku70 Celli and de Lange 2005; Celli et al. 2006 ). This process can be quantified in metaphase spreads using telomeric DNA FISH (fluorescent in situ hybridization). In mouse and human cells, chromosomes typically fuse at a frequency of 0.2-0.3 fusions per chromosome end within 72 h after inhibition of TRF2 ( Fig. 2A; Supplementary Fig.  5A ), and in TRF2-deficient mouse cells, the frequency of fusions increases to more than one fusion per chromosome after 5 d, resulting in long trains of joined chromosomes (Celli and de Lange 2005) . Most of the metaphases of MDC1 shRNA-treated mouse cells, however, did not contain joined chromosomes at 72 h after TRF2 deletion; only a small fraction of the metaphases showed a moderate number of fusions. Quantification revealed that MDC1 inhibition led to a three-to fourfold decrease in (E) Bar graph of the frequency of TIF formation. At least 100 cells were scored for five or more telomeric 53BP1, ATM-S1981-P, and ␥-H2AX foci in two independent experiments.
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telomere fusions in mouse cells ( Fig. 2A,B ) and a similar decrease in human cells ( Supplementary Fig. 5A ,B). In TRF2F/− p53 −/− mouse cells the effect of MDC1 inhibition was most prominent at the early time points of telomere deprotection (60-72 h after introduction of Cre). At later time points, most chromosomes were fused into long trains both in control cells and in MDC1 shRNAtreated cells (data not shown). The NHEJ of dysfunctional telomeres was also affected when the recruitment of MDC1 to chromatin was blocked by lowering the amount of its binding partner, ␥-H2AX, with shRNA to H2AX. A previously published shRNA resulted in efficient knockdown of H2AX in human cells (Fig. 3A) and resulted in abrogation of MDC1 foci at dysfunctional telomeres ( Fig. 3B,C) . These cells showed a threefold reduction in telomere fusions in response to inhibition of TRF2 ( Fig. 3D ,E), which is similar to the effect of MDC1 knockdown. These results indicate that ␥-H2AX-mediated recruitment of MDC1 to chromatin accelerates the rate by which dysfunctional telomeres are repaired by NHEJ.
We next asked whether MDC1 affected the removal of the telomeric 3Ј overhang, a step that may be specific to the joining of dysfunctional telomeres. Prior data have shown that the telomeric 3Ј overhang disappears after TRF2 inhibition, but recent data on mouse cells documented that this overhang removal does not occur when the NHEJ pathway is blocked (Celli and de Lange 2005; Celli et al. 2006) . In fact, when TRF2 is deleted from DNA ligase IV-or Ku70-deficient mouse cells, the overhang signals increase slightly, presumably due to degradation of the deprotected C-rich telomeric DNA strand. A similar increase in the overhang signal occurred when TRF2 was deleted from mouse cells lacking normal MDC1 levels (Fig. 2C,D) . This effect coincided with the inhibition of NHEJ by MDC1 knockdown. At later time points, the overhang signal decreased (Fig. 2D) as expected from the occurrence of fusions at that stage. Thus, MDC1 knockdown affected the initial rate of overhang loss in mouse cells, but this result would be expected from a tight coupling between NHEJ and overhang processing reported previously (Celli and de Lange 2005; Celli et al. 2006) . Further insight into the role of MDC1 in overhang processing was obtained in human cells. Previous work had shown that in human cells, overhang processing can occur before the actual joining of the telomeres, leading to the detection of telomeres with diminished overhangs that had not (yet) been joined (van Steensel et al. 1998 ). Thus, in human cells, overhang processing is not strictly coupled to NHEJ, as it is in mouse cells. This slight difference in the telomere fusion pathway in human and mouse cells allowed us to ask whether MDC1 affected the overhang processing step itself. Although MDC1 clearly affected the rate of telomere fusion in transformed human cells (Supplementary Fig. 5A,B) , there was no effect on overhang processing. After TRF2-DN expression, the same reduction in overhang signal (∼40%) occurred in MDC1 knockdown and control cells ( Supplementary Fig. 5C,D) . This result argues against a role for MDC1 in overhang processing per se and suggests that MDC1 promotes NHEJ of dysfunctional telomeres through another step.
We next asked whether the effect of MDC1 on the rate of NHEJ could be due to a change in cell cycle progression. It has not been firmly established whether the rate of NHEJ of dysfunctional mammalian telomeres is affected by the cell cycle stage . However, in fission yeast, telomere NHEJ is limited to G1 (Ferreira and Cooper 2001) , and preferential NHEJ in G1 could explain why most telomere fusions in mouse cells are of the chromosome type (both sister telomeres fused). We therefore examined the effect of MDC1 knockdown on relevant cell cycle effectors that mediate the G1/S arrest after telomere dysfunction. MDC1 status affected neither the autophosphorylation of ATM nor the phosphorylation of Chk2 after TRF2 deletion from mouse cells (Fig. 4A) . Furthermore, in human cells the up-regulation of p53 and p21 in response to TRF2-DN was unaltered by MDC1 knockdown (Fig. 4B) , and primary human fibroblasts underwent senescence within a week of TRF2 inhibition regardless of the level of MDC1 ( Fig. 4C ; data not shown). Collectively, these data indicate that the activation of the G1/S checkpoint does not require the accumulation of MDC1, 53BP1, ATM-S1981-P, or Nbs1-S343-P at the sites of telomere damage. Most likely, the ATM kinase is activated and retains the ability to phosphorylate its targets in the nucleoplasm despite the lack of stable association of ATM with the dysfunctional telomeres. The data suggested that the effect of MDC1 on NHEJ was unlikely to be due to altered effector pathways of the ATM signaling cascade. The results obtained with MDC1 knockdown in mouse cells also argued against the possibility that MDC1 affects NHEJ in a manner that involves cell cycle progression since these cells lacked a functional p53 pathway and their proliferation and BrdU uptake was not affected by MDC1 knockdown (Fig. 4D) .
(We noted that upon more prolonged culturing [>2 wk], primary human fibroblasts expressing MDC1 shRNAs sh1 or sh2 started proliferating more slowly than the control cells and attained a senescence phenotype, even in the absence of TRF2-DN [ Supplementary Fig. 6A,B ; data not shown]. A senescence response to MDC1 knockdown is consistent with the diminished proliferation and senescent phenotype of MDC1 knockout MEFs [Lou et al. 2006 ]. However, a third human MDC1 shRNA [sh3] that down-regulated MDC1 efficiently and has been used in previous studies Lukas et al. 2004; Bekker-Jensen et al. 2005 did not have this senescence phenotype. Unexpectedly, we found that this shRNA [sh3] has extensive sequence identity to the mRNA for the ATM kinase and induced a significant reduction in ATM protein levels [ Supplementary Fig.  6C,D] . Thus, MDC1 sh3 has a remarkably pathway-specific off-target effect whereby it affects both MDC1 itself and ATM, the main kinase responsible for the generation of MDC1-binding sites in damaged chromatin.)
Finally, we asked whether the effect of MDC1 on the NHEJ of dysfunctional telomeres could be explained by the diminished recruitment of 53BP1 or the Mre11 complex to sites of telomere damage. Both 53BP1 and Mre11 were knocked down efficiently in human cells using previously reported shRNAs ( Supplementary Fig. 7A,B) . Despite this, the cells showed the same frequency of telomere fusions as the controls ( Supplementary Fig.  7C,D) . The data argue that MDC1 is required to support the physiological pace of NHEJ-mediated repair of dysfunctional telomeres. We were unable to demonstrate an effect of MDC1 in the context of irradiation-induced DSBs using the Fraction of activity released (FAR) assay to monitor repair ( Supplementary Fig. 8A ,B) even though this assay showed the expected reduction in DSB repair when Phospho-3-kinase-related protein kinase (PIKK) inhibitors were applied (Supplementary Fig. 8C ). Given that the FAR assay requires ∼10 times more sites of DNA damage than are created through inhibition of TRF2, it may probe DSB repair in a range of DNA damage that is less dependent on MDC1. Thus, we have no reason to assume that the role of MDC1 in NHEJ is specific for telomere dysfunction. On the contrary, our conclusions are consistent with the lower rate of plasmid transfection in cells overexpressing a dominant-negative allele of MDC1 (Stucki et al. 2005) , the modest class switch defect of MDC1 −/− mice, and their hypersensitivity to DSBs (Lou et al. 2006) . In contrast, MDC1 −/− mice have no overt defect in V(D)J recombination, an established measure of NHEJ (Lou et al. 2006) . Therefore, it was unclear whether MDC1 promotes DSB repair through an effect on NHEJ or through its effect on cell cycle progression. This issue is clarified by our data since MDC1 affected NHEJ in the absence of a change in the cell cycle effectors of the ATM signaling pathway or discernable effects on cell cycle progression. We therefore conclude that MDC1 affects NHEJ directly. Its ability to accelerate NHEJ might be related to the interaction of MDC1 with DNA-PKcs/Ku (Lou et al. 2004 ). However, MDC1 also interacts with the homologous recombination (HR) protein Rad51 (Zhang et al. 2005) , and the relevance of MDC1's interaction with these repair proteins remains to be established. Further use of telomere dysfunction to dissect the role of MDC1 in NHEJ might be helpful in this regard.
Materials and methods
shRNA knockdown Phoenix cells were used to produce shRNA expressing pSUPERIOR retroviruses (OligoEngine). Recipient cells were infected five times every 12 h and selected in puromycin. Target sequences were luciferase, 5Ј-CG TACGCGGAATACTTCGA-3Ј (Dharmacon); hMDC1 sh1, 5Ј-GCAG AAGCCAATCAGCAAA-3Ј; hMDC1 sh2, 5Ј-AGAGGGACAATGATA CAAA-3Ј; hMDC1 sh3, 5Ј-GTCTCCCAGAAGACAGTGA-3Ј (Stewart et al. 2003) ; mMDC1 sh4, 5Ј-ACAGCATGCAGTAATTGAA-3Ј; mMDC1 sh5, 5Ј-ACACAGCCGTTCTGTCTAA-3Ј. Published targets were used for Mre11.5 and Mre6 (Pichierri and Rosselli 2004) ; 53BP1.1 and 53BP2 (Wang et al. 2002) , and H2AX-3 (Lukas et al. 2004 ). RT-PCR for mouse MDC1 was performed using oligo-dT ThermoScript RT-PCR system (Invitrogen) with 3 µg RNA (Qiagen RNAeasy) and the following primers: forward, 5Ј-CTGTCCCTGAACTGGCTGTACCAG-3Ј; reverse, 5Ј-GG TAGATGACATTTCCAAATTGGA-3Ј. GAPDH (forward, 5Ј-TGAAGG TCGGTGTGAACGGATTTGGC-3Ј; reverse, 5Ј-CATGTAGGCCATGA GGTCCACCAC-3Ј) served as a control.
Inhibition of TRF2
TRF2-DN and control ␤-galactosidase adenovirus (Karlseder et al. 1999) were used at 100 plaque-forming units (pfu) per cell for HeLa and IMR90 cells as previously described (Takai et al. 2003) . Cre-mediated TRF2 deletion in mouse cells was performed by retroviral introduction of Cre recombinase into TRF2F/− p53 
IF and IF-FISH
Cells grown on coverslips were fixed for 10 min in 2% paraformaldehyde at room temperature and permeabilized for 5 min in 0.5% NP-40. Cells were blocked 30 min in PBG (0.2% [w/v] cold water fish gelatin [Sigma G-17765] ; 0.5% BSA in PBS) and incubated for 2 h at room temperature with the following antibodies in PBG: MDC1 (ab11169, Abcam); mMDC1 MAb (J. Chen, Mayo Clinic, Rochester, MN); rabbit ␣-hTRF1, 371; 53BP1 MAb (T. Halazonetis, Wistar Institute, Philadelphia, PA); 53BP1 (100-304, Novus Biologicals); phospho-ATM-Ser 1981 (Cell Signaling); ␥-H2AX MAb (Upstate Biotechnology); phospho-Nbs1 Ser-343 (Novus Biologicals). Secondary antibodies raised against mouse and rabbit were labeled with Alexa 488 (Molecular Probes) and Rhodamine Red-X (RRX, Jackson) respectively. IF-FISH was performed as described (Herbig et al. 2004 ) using the same primary and secondary antibodies as above using a Tamra-(TTAGGG) 3 PNA telomere probe (Applied Biosystems). DNA was counterstained with 4.6-diamidino-2-phenylindole (DAPI) and slides were mounted in 90% glycerol/10% PBS containing 1 µg/mL p-phenylene diamine (Sigma). Digital images were captured with a Zeiss Axioplan II microscope with a Hamamatsu C4742-95 camera using Improvision OpenLab software.
Western blot analysis
Antibodies used for immunoblotting were as follows: MDC1 (ab11169, Abcam); 53BP1 (100-305, Novus Biologicals); rabbit ␣-Mre11, 874 (Zhu et al. 2000) ; H2AX (ab11175, Abcam); p53 (DO-1, Santa Cruz Biotechnology); p21 (F-5, Santa Cruz Biotechnology); rabbit ␣-TRF2, 647 (Zhu et al. 2000) ; rabbit ␣-mRap1, 1252 (Celli and de Lange 2005) ; Chk2 (BD Biosciences); myc (9E10, Oncogene/EMD Biosciences); ␥-tubulin (clone GTU 488, Sigma).
TelomereFISH FISH on metaphase spreads was performed as described previously (van Steensel et al. 1998 ) with a FITC-OO-(AATCCC) 3 PNA telomere probe (Applied Biosystems).
Senescence-associated ␤-galactosidase (SA-␤-gal) staining SA-␤-gal staining on IMR90 cells infected with a TRF2-DN retrovirus (pWZL-TRF2 ⌬B⌬M ) was performed as described previously (Dimri et al. 1995) . Cells were kept under selection for 10 d, replated, and stained 2 d later.
Pulse-field gel electrophoresis and in-gel detection of telomeric DNA
Pulse-field gel electrophoresis and in-gel detection of mouse telomeric DNA were done as previously described (Celli and de Lange 2005) . DNA (in plugs) was separated on a 1% agarose/0.5× TBE gel and ran for 24 h using CHEF-DRII PFGE apparatus (Bio-Rad) in 0.5× TBE running buffer (initial pulse, 5 sec; final pulse, 5 sec; 6 V/cm 2 ; at 14°C). The native gel was hybridized with a 32 P-␥ATP-labeled (CCCTAA) 4 oligonucleotide and then denatured and rehybridized. Gels were exposed onto a PhosphorImager screen overnight, and the single-stranded and total G-strand signal was quantified with ImageQuant software. The G-overhang signal was normalized to the total telomeric DNA and this normalized value was compared between samples.
BrdU incorporation
Cells grown on coverslips were incubated for 1 h in 10 µM BrdU at 37°C; fixed in 75% ethanol, 25% 0.05 M glycine (pH 2.2) for 45 min at −20°C; washed twice in PBS; and processed for IF using ␣-BrdU-FITC-conjugated antibody (BD Biosciences). 
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